Get the Stockscreener App
1.33
0.37%
-0.005
After Hours:
1.33
Pmv Pharmaceuticals Inc stock is traded at $1.33, with a volume of 271.15K.
It is down -0.37% in the last 24 hours and up +1.92% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.335
Open:
$1.32
24h Volume:
271.15K
Relative Volume:
0.55
Market Cap:
$71.10M
Revenue:
-
Net Income/Loss:
$-78.34M
P/E Ratio:
-0.8975
EPS:
-1.4819
Net Cash Flow:
$-75.02M
1W Performance:
-11.33%
1M Performance:
+1.92%
6M Performance:
-2.92%
1Y Performance:
-5.00%
1-Day Range:
$1.29
$1.38
1-Week Range:
$1.28
$1.525
52-Week Range:
$1.02
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.33 | 71.10M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure - Yahoo Finance
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Zacks Investment Research
An investor group in PMV Pharmaceuticals (NASDAQ: PMVP) is held just under a 10% stake by its warrant terms. - Stock Titan
PMV Pharmaceuticals, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (PMVP) - Traders Union
PMV Pharmaceuticals, Inc. (PMVP) Earnings Date, Reports and Estimates - Traders Union
PMV Pharma appoints Philip Herman as CCO - thepharmaletter.com
symbol__ Stock Quote Price and Forecast - cnn.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
PMVP SEC Filings, Jul-Aug 2025PMV Pharmaceuticals, Inc. Filing Archive - Stock Titan
PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de
PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - AD HOC NEWS
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals (PMVP) Updates Interim Ovarian Cancer Trial Results Amid Valuation Challenges - GuruFocus
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks
PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView
PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com
Ovarian cancer trial reports a 46% response rate; FDA filing planned - Stock Titan
PMV (PMVP) Quarter in Focus: Profit Per Share Surpasses Its Benchmark for the Current Session; Stock Move - careplusvn.com
ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView
PMV (PMVP) Watch: Moves 1.15% Higher to $1.31; Price Context: Price Remains Between $1.24 Support and $1.38 Resistance in the Latest SessionValue Factor - vinanet.vn
PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the DayAnalyst Coverage Count - vinanet.vn
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
PMV Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
PMV Pharma Reports $18.1 Million Second-Quarter Net Loss - Quiver Quantitative
PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA - Stock Titan
PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission - TradingView
Press Release: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - Moomoo
PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMV Pharmaceuticals Inc (PMVP) Stock News Today - TradingKey
PMVP Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
PMV Pharmaceuticals Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Thursday - MarketBeat
PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sio Capital discloses 4.94% PMV Pharmaceuticals (PMVP) stake below 5% threshold - stocktitan.net
PMV Pharmaceuticals Inc (PMVP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMV Pharmaceuticals Inc (PMVP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PMV Pharmaceuticals Inc (PMVP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PMVP|PMV Pharmaceuticals Inc|Price:1.140|Chg%:+0.020 - TradingKey
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):